LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented results at the virtual 2021 ASCO Annual Meeting comparing the diarrhea mitigation ...

Puma Biotechnology announced interim 5-year disease free survival data from its Phase III Trial of PB272 (Neratinib) in extended adjuvant HER2-positive early stage breast cancer (ExteNET Trial).

Results show continued efficacy of neratinib in patients with HER2-positive early stage breast cancer ExteNET was a multicenter, randomized, double-blind, Phase III trial of 2,840 HER2-positive eBC ...

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive, hormone receptor-positive (HR+), ...

These data were presented in mid-December 2015. There was a significant reduction in grade 3 diarrhea among patients treated with neratinib and prophylactic loperamide (sold under the brand name ...